secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-07-20T20:00:14+00:00
Accession:  0001193125-26-308899
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Damora Therapeutics completes redomestication from Delaware to Cayman Islands
-----------------------------------------------------------------------------

- Redomestication effective July 16, 2026; each common share converted 1:1 into ordinary shares of Cayman company.
- New CUSIP G2646Y104; ordinary shares continue trading on Nasdaq under symbol DMRA as of July 20, 2026.
- No change in business, management, obligations, assets, or liabilities; company remains a U.S. corporation for tax purposes.
- Stockholders approved the redomestication at a special meeting on February 9, 2026.
- Company also entered into indemnification agreements with directors and executive officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526308899/0001193125-26-308899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526308899/dmra-20260716.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-308899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer